Last reviewed · How we verify
Transplantation of cord blood expanded with UM171 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Transplantation of cord blood expanded with UM171 (Transplantation of cord blood expanded with UM171) — Maisonneuve-Rosemont Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Transplantation of cord blood expanded with UM171 TARGET | Transplantation of cord blood expanded with UM171 | Maisonneuve-Rosemont Hospital | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Transplantation of cord blood expanded with UM171 CI watch — RSS
- Transplantation of cord blood expanded with UM171 CI watch — Atom
- Transplantation of cord blood expanded with UM171 CI watch — JSON
- Transplantation of cord blood expanded with UM171 alone — RSS
Cite this brief
Drug Landscape (2026). Transplantation of cord blood expanded with UM171 — Competitive Intelligence Brief. https://druglandscape.com/ci/transplantation-of-cord-blood-expanded-with-um171. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab